 |
| Howard S. Jonas |
Chairman of the Board
|
|
|
Howard S. Jonas has served as Chairman of the Board of Directors of the Company since August 17, 2017 and served as Chief Executive Officer from March 8, 2018 through April 30, 2021. Mr. Jonas has been a director of Rafael Pharmaceuticals since April 2013 and was appointed Chairman of the Board in April 2016. Mr. Jonas founded IDT in August 1990, and has served as Chairman of its Board of Directors since its inception. Mr. Jonas served as Chief Executive Officer of IDT from October 2009 through December 2013. Mr. Jonas has served as Chairman of the Board of Directors of Genie Energy Ltd. since January 2011, when it was spun off from IDT, and served as Chief Executive Officer of Genie from January 2014 until November 2017. Mr. Jonas served as the Chairman of the Board of Zedge, Inc., a former subsidiary of IDT that was spun off to stockholders in June 2016, from June 2016 to November 2016, and as the Vice Chairman of Zedge since November 2016. Mr. Jonas also serves as Chairman of the Board of IDW Media Holdings, Inc., a former subsidiary of IDT that was spun off to stockholders in September 2009 and served as Chief Executive officer until April 2020. Mr. Jonas is also the founder and has been President of Jonas Media Group (f/k/a Jonas Publishing) since its inception in 1979. Mr. Jonas received a B.A. in Economics from Harvard University. |
|
 |
| Ameet Mallik |
Chief Executive Officer
|
|
|
| Ameet Mallik has served as the Company’s Chief Executive Officer since May 1,
2021. Mr. Mallik served as Executive Vice
President and Head, U.S. Oncology of Novartis from November 2017 through April
2021. In this role, Mr. Mallik was responsible for Novartis’s commercial and
medical oncology operations in the United States. From November 2015 to
November 2017, Mr. Mallik served as Global Head, Marketing, Value and Access,
and from April 2014 to November 2015 as Head, Latin America and Canada, both
for Novartis Oncology. Mr. Mallik began his career at Novartis as Head of
Strategic Planning and has held a number of commercial leadership roles at
Novartis and Sandoz. At Sandoz, Mr. Mallik was Head of Biopharmaceuticals &
Oncology Injectables at Sandoz. Mr. Mallik previously worked as an Associate
Principal at McKinsey and Company. Mr. Mallik holds an M.B.A. from The
Wharton School at the University of Pennsylvania, and an M.S. in Biotechnology
and B.S. in Chemical Engineering, both from Northwestern University. |
|
 |
| Menachem Ash |
President and General Counsel
|
|
|
| Menachem Ash has served as the Company’s President since July 2017 and General Counsel since March 2018. He has served as Executive Vice President of Strategy and Legal Affairs of IDT since October 2012. Mr. Ash served as the managing attorney of IDT’s legal department from June 2011 to October 2012. Mr. Ash has served as senior counsel to several IDT divisions since he joined IDT in July 2004, including IDT Telecom and IDT Carmel. Prior to joining IDT, Mr. Ash served as General Counsel to Telstar International, Inc., a telecommunications services provider. Mr. Ash also worked at KPMG as a senior associate in its tax group focusing on financial services and technology companies. He is a graduate of Brooklyn College and the Benjamin N. Cardozo School of Law. |
|
 |
| David A. Polinsky, Esq. |
Chief Financial Officer
|
|
|
| David Polinsky has served as Chief Financial Officer of the Company since December 2017. Mr. Polinsky co-founded Rafael Pharmaceuticals and has served as its Vice President, General Counsel and Corporate Secretary from 2002, and as President, General Counsel and Secretary from 2016 through March 2018. He also served on Rafael Pharmaceutical’s Board from 2002 until 2014. Mr. Polinsky serves as treasurer of Barer Institute, Inc. Mr. Polinsky also serves as Chairman of the Board of TheGiftBox, a company he co-founded in the technology sector and is a member of the board of Innovative Food Holdings Inc. Prior to co-founding Rafael Pharmaceuticals, he served as Vice President and General Counsel for a New York-based real estate focused investment and management company, Square Management Corp., leading the investment analysis in and management of residential, office, retail and development properties. Previously and in partnership with the Honorable Edward I. Koch, former Mayor of New York City, Mr. Polinsky founded and served as CEO of a company that licensed and developed TheLaw.com. Mr. Polinsky earned his Juris Doctorate from Fordham University School of Law in 1996 and his Bachelor of Arts from Yeshiva University. Mr. Polinsky also earned the CFA Institute’s Investment Foundations certificate in 2017. |
|
 |
| William 'Bill' Conkling |
Chief Commercial Officer
|
|
|
| William Conkling has served as Chief Commercial Officer of the Company since March 2021. Mr. Conkling has over 20 years’ experience in the pharmaceutical/biotech industry working in Oncology. He has extensive experience launching innovative oncology products. His experience spans all areas of commercialization including marketing, sales, market access, commercial operations and business development. Prior to joining the Company, Mr. Conkling helped lead the launch of Trodelvy at Immunomedics Inc. (acquired by Gilead for $21B in October 2020) as the VP Sales, Marketing and Market Access. Mr. Conkling also spent over 10 years at Novartis Oncology where he helped lead the launch of the first CAR-T therapy approved in the US as the Global Commercial Leader — Kymriah. Mr. Conkling earned his Bachelor’s Degree from Fordham University and his Master’s in Business Administration from New York University Stern School of Business in 1998.
|
|
